Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30858342 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL30796039 | 0.93 | L3MBTL1 (0.59) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL30014462 | 0.90 | ALDH1A1 (0.50) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25901418 | 0.88 | HDAC2 (0.46) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL8251175 | 0.88 | L3MBTL1 (0.73) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL30858329 | 0.88 | L3MBTL1 (0.59) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL354715 | 0.88 | L3MBTL1 (0.59) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL27202624 | 0.87 | L3MBTL1 (0.56) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL354114 | 0.86 | L3MBTL1 (0.58) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL30414220 | 0.86 | LMNA (0.49) | MAPTKMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108404-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-03-27 | — | — | US | disclosed |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4384521-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-117794936-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ITEOS BELGIUM S A (BE) | 2023-03-30 | — | — | US | disclosed |
| WO-2023018237-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
| WO-2009079593-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-7361658-B2 | 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl)piperidine-4-carboxylic acid; non-peptide thrombopoietin receptor (c-mpl-Ba/F3) ligand; less immunogenicity; platelet activator based on megakaryocyte colony; thrombocytopenia; orally | ASTELLAS PHARMA INC. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060194844-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647553-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | L3MBTL1 706/4885MAPT 1730/4885KMT2A 1299/4885 |
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | L3MBTL1 964/4885MAPT 2055/4885KMT2A 1840/4885 |
| US-20060194844-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, MATK | L3MBTL1 245/4885MAPT 4790/4885KMT2A 368/4885 |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | L3MBTL1 2754/4885MAPT 4689/4885KMT2A 1465/4885 |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | L3MBTL1 3830/4885MAPT 3094/4885KMT2A 1387/4885 |
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | L3MBTL1 2754/4885MAPT 4689/4885KMT2A 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.